⚡ Interrogation des APIs scientifiques en cours…
⚡ Interrogation des APIs scientifiques en cours…
Authors' conclusion
Does not affect the score
Publi-Score
Fidelity
Abstract (PubMed)
In an international, randomized, double-blind, placebo-controlled, phase 3 trial, 19,630 SARS-CoV-2-negative participants received Ad26.COV2.S and 19,691 received placebo. Ad26.COV2.S efficacy against moderate to severe-critical Covid-19: 66.9% (95% CI 59.0–73.4) at ≥14 days, 66.1% (55.0–74.8) at ≥28 days. Efficacy against severe-critical disease: 76.7% at ≥14 days, 85.4% at ≥28 days. In South Africa (94.5% 20H/501Y.V2 variant), efficacy was 52.0% and 64.0% against moderate to severe-critical disease. Reactogenicity was higher with Ad26.COV2.S. Serious adverse events were balanced between groups.
Coeff. authors = avg(0.40, 0.80) = 0.60
Coeff. editorial = avg(1.00, 0.90) = 0.95
min(0.60, 0.95) = 0.60← lowest dominates
Alert signal : eoc → Coefficient forced to 0.3
Expression of Concern published
Final coefficient : 0.60
Final score = 55.8/100 × 0.60 × 100 = 34/100
Adverse events of active and placebo groups in SARS-CoV-2 vaccine randomized trials: A …
Amanzio M — 2022 · Lancet Reg Health Eur
Contrasted resultsNeutralizing antibody levels are highly predictive of immune protection from symptomati…
Khoury DS — 2021 · Nature medicine
Contrasted resultsAssociation Between BNT162b2 Vaccination and Long COVID After Infections Not Requiring …
Azzolini E — 2022 · JAMA
Contrasted resultsMeta-analysis of Randomized Trials of Ivermectin to Treat SARS-CoV-2 Infection
Hill A — 2021 · Open Forum Infectious Diseases
Contrasted resultsIvermectin for Prevention and Treatment of COVID-19 Infection: A Systematic Review, Met…
Bryant A — 2021 · American journal of therapeutics